2024修订版AD生物学与临床分期标准在中国记忆门诊的临床评估
本研究连续纳入1214例接受淀粉样蛋白PET和tau PET的记忆门诊参与者,按2024修订版AD标准对淀粉样蛋白阳性者进行临床与生物学分期,发现临床-生物学分期不一致常见,其中典型组占50.4%、易感组占40.3%、韧性组占9.3%。韧性组认知表现更优、受教育年限更高且AD特征区皮层厚度和体积更大,易感组则认知更差、皮层厚度和体积更小,血浆p-tau217随tau PET分期进展而逐步升高。
要点
- 淀粉样蛋白阳性者中临床与生物学分期不一致常见,易感组占40.3%。
- 韧性组认知表现更优、受教育程度更高且AD特征区皮层更厚。
- 血浆p-tau217随tau PET分期进展而逐步升高,可辅助评估tau病理严重度。
核心结论
- 在三级记忆门诊中国队列中,2024修订版AD标准下淀粉样蛋白阳性者临床-生物学分期不一致常见,不同亚组具有独特的认知、教育、生物标志物和神经解剖特征,支持该分期框架的临床相关性。
研究设计与样本
- 连续纳入1214例接受淀粉样蛋白PET和tau PET的记忆门诊参与者,其中818例淀粉样蛋白阳性,按2024修订版标准进行临床分期(0-6)和生物学分期(A-D)。
- 在379例淀粉样蛋白阳性参与者中测量血浆p-tau217,采用广义线性模型并校正相关协变量,多重比较采用错误发现率校正。
主要发现
- 818例淀粉样蛋白阳性者中,典型组412例(50.4%)、易感组330例(40.3%)、韧性组76例(9.3%)。
- 血浆p-tau217随tau PET分期进展而逐步升高(趋势P<0.001),D期(1.31 pg/mL)显著高于A期(0.56 pg/mL,q=0.029)和C期(0.95 pg/mL,q=0.013)。
- 与典型组相比,韧性组认知表现更优(如MMSE:β=8.56,q<0.001)、受教育年限>9年者比例更高(74.1% vs 45.1%,q=0.020)、AD特征区皮层厚度(t=3.033,q=0.005)和体积(t=3.209,q=0.003)更大。
- 与典型组相比,易感组认知评分更差(如MMSE:β=-8.29,q<0.001)、AD特征区皮层厚度(t=-2.872,q=0.005)和体积(t=-2.751,q=0.007)更小,血管危险因素负担数值上更高。
关键数值与推荐
- 临床分期为0-6期,生物学分期为A-D期,淀粉样蛋白阳性者按临床与生物学分期一致性分为典型(一致)、易感(临床>生物学)和韧性(临床<生物学)。
- 血浆p-tau217在tau PET D期为1.31 pg/mL,A期为0.56 pg/mL(q=0.029),C期为0.95 pg/mL(q=0.013)。
临床怎么用
- 在记忆门诊中可应用2024修订版AD标准同时评估生物学与临床分期,识别临床-生物学分期不一致的易感与韧性亚组。
- 血浆p-tau217可作为血液标志物反映tau病理严重程度,辅助tau PET分期评估。
局限性
- 研究为单中心三级记忆门诊队列,结果外推至其他人群需谨慎。
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The 2024 revised criteria introduced an integrated framework for staging Alzheimer disease (AD) across biological and clinical dimensions. However, how this criterion characterizes clinical and biological features in populations outside the original development setting, particularly in non-Western and specialized clinic settings, remains insufficiently described. METHODS: We consecutively enrolled 1,214 memory clinic participants who underwent both amyloid-PET and tau-PET imaging. Among amyloid-positive (A+) individuals, clinical stages (0-6) and biological stages (A-D) were assigned according to the 2024 criteria. Participants were classified as typical (concordant stages), susceptible (clinical > biological), or resilient (clinical < biological). Plasma p-tau217 was measured in 379 A+ participants. Associations were examined using generalized linear models adjusted for relevant covariates, with false discovery rate correction for multiple comparisons. RESULTS: Among the 1,214 participants, 818 were amyloid positive, comprising 412 (50.4%) typical, 330 (40.3%) susceptible, and 76 (9.3%) resilient individuals. Plasma p-tau217 increased progressively across advancing tau PET stages (p for trend <0.001), with significantly higher levels in stage D (1.31 pg/mL) compared with stage A (0.56 pg/mL, q = 0.029) and stage C (0.95 pg/mL, q = 0.013). Compared with the typical group, resilient individuals demonstrated superior cognitive performance (e.g., Mini-Mental State Examination [MMSE]: β = 8.56, q < 0.001), higher educational attainment (>9 years: 74.1% vs 45.1%, q = 0.020), and greater AD-signature regional cortical thickness (t = 3.033, q = 0.005) and volume (t = 3.209, q = 0.003). Conversely, susceptible individuals exhibited inferior cognitive scores (e.g., MMSE: β = -8.29, q < 0.001), reduced cortical thickness (t = -2.872, q = 0.005), and volume (t = -2.751, q = 0.007) in AD-signature regions and a numerically higher burden of vascular risk factors. DISCUSSION: In a large cohort from a specialized tertiary memory clinic, clinical-biological stage discordance under the 2024 AD criteria was common among amyloid-positive individuals. Distinct cognitive, educational, biomarker, and neuroanatomic profiles characterized susceptible, typical, and resilient subgroups. In addition, plasma p-tau217 showed a stepwise increase across tau PET stages, supporting its utility as a blood-based marker of tau pathology severity. These findings support the clinical relevance of the revised staging framework and may inform future refinements of AD diagnostic guidelines. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the 2024 revised biological and clinical criteria for AD demonstrate clinical utility in a Chinese cohort from a specialized tertiary memory clinic.
引用
- Wang ZY, Xin JW, Wang MY, et al. Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China. Neurology. 2026. PMID: 42314105. doi:10.1212/WNL.0000000000218184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。